aTyr Pharma Inc  

(Public, NASDAQ:LIFE)   Watch this stock  
Find more results for LIFE
+0.09 (1.07%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.27 - 8.71
52 week 8.12 - 28.29
Open 8.47
Vol / Avg. 0.00/78,343.00
Mkt cap 198.88M
P/E     -
Div/yield     -
EPS -1.90
Shares 23.65M
Beta     -
Inst. own 71%
Nov 11, 2015
aTyr Pharma Inc at Credit Suisse Healthcare Conference
Nov 10, 2015
Q3 2015 aTyr Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.86% -80.59%
Return on average equity -33.85% -
Employees 53 -
CDP Score - -


3545 John Hopkins Ct Ste 250
SAN DIEGO, CA 92121-1115
United States - Map
+1-858-7318389 (Phone)
+1-858-7318394 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines, a class of naturally occurring proteins that promotes homeostasis. The Company’s Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction, including severe diseases of the lung, gut, skin, brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue, an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.

Officers and directors

John D. Mendlein Ph.D. Chief Executive Officer and Executive Chairman, Board of Directors
Age: 55
Bio & Compensation  - Reuters
Stan Blackburn Acting Chief Financial Officer, Principal Financial Officer,
Bio & Compensation  - Reuters
John T. Blake Chief Accounting Officer, Vice President - Finance
Age: 39
Bio & Compensation  - Reuters
Melissa A Ashlock Vice President - External Scientific Alliances and Human Genetics
Age: 57
Bio & Compensation  - Reuters
Kelly Blackburn Vice President - Clinical Affairs
Age: 51
Bio & Compensation  - Reuters
Holly D Chrzanowski Vice President - Enterprise Talent and Organization
Age: 49
Bio & Compensation  - Reuters
Andrew Cubitt Vice President - Product Protection
Age: 52
Bio & Compensation  - Reuters
John C McKew Vice President - Research
Age: 51
Bio & Compensation  - Reuters
Fred Ramsdell Vice President - Immunology
Age: 54
Bio & Compensation  - Reuters
John K. Clarke Non-Executive Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters